Cargando…

KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells

Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have been widely adopted in colorectal cancer (CRC), but those to predict chemotherapy sensitivity remain poorly defined. We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yu-Lin, Liau, Jau-Yu, Yu, Shan-Chi, Ou, Da-Liang, Lin, Liang-In, Tseng, Li-Hui, Chang, Yih-Leong, Yeh, Kun-Huei, Cheng, Ann-Lii
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508995/ https://www.ncbi.nlm.nih.gov/pubmed/23209813 http://dx.doi.org/10.1371/journal.pone.0050701

Ejemplares similares

Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients
por: Lin, Yu-Lin, et al.
Publicado: (2014)

Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study
por: Chen, Kuo-Hsing, et al.
Publicado: (2016)

Clinicopathological features and prognosis of patients with de novo versus nevus-associated melanoma in Taiwan
por: Sheen, Yi-Shuan, et al.
Publicado: (2017)

A clinicopathological analysis of 153 acral melanomas and the relevance of mechanical stress
por: Sheen, Yi-Shuan, et al.
Publicado: (2017)

5-Fluorouracil-related encephalopathy: at least two distinct pathogenetic mechanisms exist - reply
por: Yeh, Kun-Huei, et al.
Publicado: (1998)

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer
por: Hsieh, Chi-Che, et al.
Publicado: (2022)

Insulin-Like Growth Factor II mRNA-Binding Protein 3 Expression Correlates with Poor Prognosis in Acral Lentiginous Melanoma
por: Sheen, Yi-Shuan, et al.
Publicado: (2016)

Combined squamous cell carcinoma and Merkel cell carcinoma of the vulva: Role of human papillomavirus and Merkel cell polyomavirus
por: Chen, Chien-Heng, et al.
Publicado: (2015)

Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy
por: Tsubaki, Masanobu, et al.
Publicado: (2023)

Prognosis of tumor infiltrating lymphocytes in operable tongue cancer patients
por: Chen, Wan-Yu, et al.
Publicado: (2014)

Oxaliplatin-Induced DHX9 Phosphorylation Promotes Oncogenic Circular RNA CCDC66 Expression and Development of Chemoresistance
por: Lin, Ya-Chi, et al.
Publicado: (2020)

Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer
por: To, Kenneth K.W., et al.
Publicado: (2016)

Metformin Enhancement of Therapeutic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells and Nude Mice
por: Yip, Kwan-Ling, et al.
Publicado: (2022)

Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma
por: Tao, Yuquan, et al.
Publicado: (2018)

A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
por: Kim, Su-Hyun, et al.
Publicado: (2018)

Tegafur–Uracil/Leucovorin Plus Oxaliplatin (TEGAFOX) as Consolidation Regimen after Short-Course Radiotherapy Is Effective for Locally Advanced Rectal Cancer
por: Liao, Chun-Kai, et al.
Publicado: (2022)

Enhancement of oxaliplatin-induced colon cancer cell apoptosis by alantolactone, a natural product inducer of ROS
por: Cao, Peihai, et al.
Publicado: (2019)

Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study
por: Teng, Chieh-Lin Jerry, et al.
Publicado: (2015)

Risk factors of recurrence and distant metastasis in primary cutaneous melanoma in Taiwan
por: Lee, Tung-Lin, et al.
Publicado: (2021)

Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells
por: Shi, Ying, et al.
Publicado: (2016)

Advanced Cross-Correlation Function Application to Identify Arterial Baroreflex Sensitivity Variations From Healthy to Diabetes Mellitus
por: Yeh, Shoou-Jeng, et al.
Publicado: (2022)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer
por: Birgisson, Helgi, et al.
Publicado: (2015)

Towards patient-specific cardiovascular modeling system using the immersed boundary technique
por: Tay, Wee-Beng, et al.
Publicado: (2011)

Copy Number Alterations of Depressed Colorectal Neoplasm Predict the Survival and Response to Oxaliplatin in Proximal Colon Cancer
por: Chang, Li-Chun, et al.
Publicado: (2020)

IκB kinases increase Myc protein stability and enhance progression of breast cancer cells
por: Yeh, Pei-Yen, et al.
Publicado: (2011)

The differences on efficacy of oxaliplatin in locally advanced colon cancer between mucinous and nonmucinous adenocarcinoma
por: Yu, Dehao, et al.
Publicado: (2018)

PB1778: PAN-PIM KINASE INHIBITOR PIM447 SHOWS SUPERIOR ANTI-LEUKEMIC EFFECT IN ACUTE ERYTHROID LEUKEMIA
por: Tseng, Chi-Yang, et al.
Publicado: (2023)

Potentiating the Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Pathway
por: Ou, Da-Liang, et al.
Publicado: (2013)

A KRAS-Associated Signature for Prognostic, Immune and Chemical Anti-Cancer Drug-Response Prediction in Colon Cancer
por: Luo, Kangjia, et al.
Publicado: (2022)

β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1
por: Li, Xiaoqiang, et al.
Publicado: (2016)

Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis
por: Lin, Jin-Fei, et al.
Publicado: (2022)

Thymopentin-Mediated Inhibition of Cancer Stem Cell Stemness Enhances the Cytotoxic Effect of Oxaliplatin on Colon Cancer Cells
por: Yu, Peng-Cheng, et al.
Publicado: (2022)

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017)

Chemo-Immunotherapy with Oxaliplatin and Interleukin-7 Inhibits Colon Cancer Metastasis in Mice
por: Gou, Hong-Feng, et al.
Publicado: (2014)

Effects of oxaliplatin on mouse myenteric neurons and colonic motility
por: Wafai, Linah, et al.
Publicado: (2013)

Oxaliplatin and infliximab synergize to induce regression of colon cancer
por: Huang, Di, et al.
Publicado: (2018)

Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
por: Kuo, Sung-Hsin, et al.
Publicado: (2019)

Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma
por: Kuo, Sung-Hsin, et al.
Publicado: (2022)

Treatment outcome analysis of bevacizumab combined with cyclophosphamide and oxaliplatin in advanced pseudomyxoma peritonei
por: Zhang, Ying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lhd2ilhkivvd481c9tghjpafjf